Stereotaxis (STXS) Q3 2026 Earnings Call Transcript
Stereotaxis (STXS) reported Q3 2026 revenue growth of 60% YoY, driven by sales of GenesisX and Synchrony systems. Key milestones include FDA clearance for GenesisX interoperability and a collaboration with Canon. Robotic catheter revenue is expected to reach several million dollars this year, despite supply constraints. The company anticipates resolving supply issues in early 2027 and sees growth opportunities in capital systems and disposable revenue.
How this was made

The 30-second read
Why it matters
The earnings beat and partnership could drive short-term price upside, but supply chain issues remain a risk.
Market read
Earnings and partnership news provide a fresh catalyst for STXS, with modest upside potential.
What to watch
Potential delays in scaling Osypka's production could dampen future growth.
Background
Stereotaxis reported its Q3 2026 earnings, highlighting revenue growth, FDA clearance, and a new collaboration with Canon.
Ticker impact
Q3 2026 earnings call disclosed system revenue of $3M, up 60% YoY, and new FDA clearance and Canon collaboration.
potential modest upside as investors price in higher-than-expected revenue and new partnership news
Fresh earnings numbers and concrete partnership announcements provide a clear catalyst.
Market effects
Positive signal for medical robotics and interventional cardiology equipment sector.
U.S. and European markets may see modest gains in healthcare equipment stocks.
Limited to niche medical device segment.
Counterpoint
Revenue growth may be offset by supply constraints and limited catheter availability.
Key entities
- partnerCanon
Collaborating on X‑ray compatibility for GenesisX system.
- contract manufacturerOsypka
Facing production shortfalls for MAGIC catheters.
